{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-135264","form_type":"8-K","ticker":null,"cik":"0001785173","company_name":"89bio, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.097411+00:00","generated_at":"2026-06-02T06:40:17.508584+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"89bio reports Q1 net loss of $51.7M; initiates Phase 3 MASH trial","bullets":["Net loss $51.7M vs $28.8M YoY; R&D expenses $47.4M (up from $22.3M) on trial ramp-up.","Cash, equivalents & marketable securities $562.3M as of March 31, 2024.","Initiated Phase 3 ENLIGHTEN-Fibrosis trial in MASH F2-F3; ENLIGHTEN-Cirrhosis expected Q2 2024.","EMA granted PRIME status for pegozafermin in MASH; 48-week extension data at EASL June 8.","ENTRUST Phase 3 in severe hypertriglyceridemia enrollment ongoing; topline data expected 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-135264","json":"https://secwatch.observer/filing/0001193125-24-135264.json","markdown":"https://secwatch.observer/filing/0001193125-24-135264.md","text":"https://secwatch.observer/filing/0001193125-24-135264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785173/000119312524135264/0001193125-24-135264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785173/000119312524135264/d793786d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:40:17.508584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13860b0e5ba54010acd2ebd37161b9c8fade273e","claim":"89bio, Inc. reported the first quarter ended March 31, 2024 results: net income $51.7 million.","evidence_excerpt":"89bio reported a net loss of $51.7 million for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312524135264/0001193125-24-135264-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$51.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}